rapid
increas
nosocomi
methicillinresist
staphylococcu
aureu
mrsa
infect
vancomycinresist
enterococci
vre
univers
hospit
taiwan
found
notic
rise
mrsa
vre
significantli
correl
increas
consumpt
glycopeptid
inhibitor
combin
extendedspectrum
cephalosporin
carbapenem
fluoroquinolon
pearson
correl
coeffici
p
minimum
inhibitori
concentr
mic
nondupl
blood
isol
mrsa
nondupl
isol
vancomycinresist
enterococcu
faecali
vancomycinresist
enterococcu
faecium
caus
nosocomi
infect
recov
variou
clinic
specimen
patient
treat
hospit
nine
antimicrobi
agent
determin
agar
dilut
method
isol
suscept
linezolid
inhibit
mgl
tigecyclin
mrsa
isol
inhibit
daptomycin
mgl
includ
two
isol
mrsa
heteroresist
vancomycin
daptomycin
twofold
better
activ
vancomycinresist
e
faecali
mic
mgl
vancomycinresist
e
faecium
mic
mgl
decreas
suscept
vancomycinresist
e
faecium
mrsa
quinupristindalfopristin
nonsuscept
respect
found
telithromycin
poor
activ
isol
test
mic
mgl
linezolid
daptomycin
tigecyclin
may
repres
therapeut
option
infect
caus
resist
gramposit
organ
antimicrobi
drug
resist
becom
great
public
health
problem
worldwid
among
resist
gramposit
pathogen
methicillin
oxacillin
resist
staphylococcu
aureu
mrsa
vancomycinintermedi
resist
aureu
visa
vrsa
vancomycinresist
enterococci
vre
great
concern
import
organ
caus
variou
type
nosocomi
infect
increas
preval
resist
pathogen
hospit
frequent
relat
high
select
pressur
antibiot
includ
extendedspectrum
cephalosporin
fluoroquinolon
glycopeptid
newer
antimicrobi
agent
oxazolidinon
daptomycin
streptogramin
novel
antimicrobi
mechan
develop
treat
infect
caus
resist
gramposit
bacteria
among
agent
linezolid
introduc
taiwan
quinupristindalfopristin
daptomycin
avail
within
next
year
taiwan
preval
mrsa
hospit
steadili
increas
past
decad
moreov
mrsa
strain
reduc
suscept
vancomycin
ie
visa
heterogen
resist
visa
vre
caus
invas
nosocomi
infect
report
recent
studi
aim
describ
trend
increas
preval
mrsa
vre
nation
taiwan
univers
hospit
ntuh
elucid
relationship
annual
antibiot
consumpt
hospit
trend
resist
determin
potenti
role
newer
agent
treatment
infect
caus
resist
pathogen
ntuh
univers
hospit
locat
northern
taiwan
nosocomi
infect
control
committe
hospit
establish
definit
nosocomi
infect
follow
nation
nosocomi
infect
surveil
guidelin
number
annual
patientday
hospit
increas
slightli
decreas
owe
sever
acut
respiratori
syndrom
epidem
taiwan
antimicrobi
agent
teicoplanin
introduc
hospit
antibiot
linezolid
quinupristindalfopristin
telithromycin
daptomycin
avail
hospit
studi
period
data
annual
consumpt
defin
daili
dose
ddd
per
patientday
extendedspectrum
cephalosporin
cefotaxim
ceftriaxon
ceftazidim
flumoxef
cefepim
cefpirom
inhibitor
combin
ticarcillinclavulan
acid
piperacillintazobactam
carbapenem
imipenem
meropenem
glycopeptid
vancomycin
teicoplanin
aminoglycosid
amikacin
gentamicin
tobramycin
inject
ciprofloxacin
fluoroquinolon
ciprofloxacin
oral
inject
oral
levofloxacin
moxifloxacin
linezolid
obtain
pharmaci
depart
hospit
determin
tempor
trend
mrsa
vre
caus
nosocomi
infect
ntuh
data
disk
diffus
suscept
aureu
oxacillin
enterococci
vancomycin
among
isol
recov
retriev
annual
summari
document
suscept
test
aureu
enterococci
follow
nation
committe
clinic
laboratori
standard
nccl
guidelin
staphylococcu
aureu
atcc
e
faecali
atcc
use
control
strain
routin
disk
suscept
test
methicillin
resist
aureu
routin
screen
growth
isol
trypticas
soy
agar
plate
contain
oxacillin
mgl
plu
nacl
incub
ambient
air
c
h
vancomycin
resist
enterococci
confirm
growth
isol
brain
heart
infus
bhi
agar
vancomycin
mgl
incub
ambient
air
c
h
staphylococcu
aureu
atcc
aureu
atcc
e
faecali
atcc
e
faecali
atcc
use
control
strain
minimum
inhibitori
concentr
mic
suscept
pattern
test
consecut
nondupl
blood
isol
mrsa
patient
develop
nosocomi
bacteraemia
hospit
isol
vancomycinresist
e
faecali
isol
vancomycinresist
e
faecium
variou
clinic
specimen
patient
treat
two
isol
heteroresist
visa
two
patient
recurr
bacteraemia
found
also
includ
analysi
isol
store
c
trypticas
soy
broth
bbl
microbiolog
system
cockeysvil
md
usa
supplement
glycerol
test
follow
antimicrobi
agent
provid
manufactur
use
studi
penicillin
tetracyclin
sigma
chemic
co
st
loui
mo
usa
oxacillin
bristolmy
squibb
princeton
nj
usa
vancomycin
eli
lilli
co
indianapoli
usa
teicoplanin
quinupristindalfopristin
telithromycin
aventi
pharma
romainvil
franc
linezolid
pharmacia
kalamazoo
mi
usa
tigecyclin
wyethayerst
pearl
river
ny
usa
daptomycin
cubist
pharmaceut
lexington
usa
mic
determin
isol
use
agar
dilut
method
broth
microdilut
method
daptomycin
accord
guidelin
establish
nccl
isol
grown
overnight
trypticas
soy
agar
plate
supplement
sheep
blood
bbl
microbiolog
system
c
h
bacteri
inocula
prepar
suspend
freshli
grown
bacteria
steril
normal
salin
adjust
mcfarland
standard
suscept
test
mrsa
vre
isol
daptomycin
dryform
microtitr
plate
contain
daptomycin
physiolog
concentr
ca
mgl
manufactur
trek
diagnost
system
cleveland
oh
usa
use
suscept
test
mrsa
oxacillin
muellerhinton
agar
bbl
microbiolog
system
supplement
nacl
use
suscept
test
mrsa
agent
vre
unsuppl
muellerhinton
agar
bbl
microbiolog
system
use
use
steer
replic
organ
densiti
colonyform
unit
cfu
spot
inocul
onto
appropri
plate
variou
concentr
antimicrobi
agent
incub
c
h
ambient
air
regular
qualiti
assur
perform
among
isol
process
american
type
cultur
collect
atcc
control
strain
aureu
atcc
aureu
atcc
e
faecali
atcc
e
faecali
atcc
isol
classifi
suscept
intermedi
resist
accord
nccl
criteria
phenotyp
vana
vanb
vanc
vre
defin
describ
previous
nccl
mic
breakpoint
interpret
suscept
telithromycin
enterococcu
speci
tigecyclin
enterococcu
staphylococcu
speci
pearson
correl
coeffici
use
determin
relationship
annual
antibiot
consumpt
annual
rate
mrsa
vre
caus
nosocomi
infect
pvalu
consid
statist
signific
mic
antimicrobi
agent
test
two
control
strain
within
rang
provid
nccl
mic
vancomycinresist
e
faecium
mrsa
vancomycinresist
e
faecali
isol
test
inhibit
tigecyclin
mgl
includ
mrsa
e
faecali
isol
highli
resist
tetracyclin
mic
mgl
tigecyclin
greater
activ
vancomycinresist
e
faecium
isol
tetracyclin
two
isol
heteroresist
visa
suscept
quinupristindalfopristin
linezolid
highli
resist
tetracyclin
mic
mgl
telithromycin
mic
mgl
two
isol
daptomycin
mic
mgl
tigecyclin
mic
mgl
studi
two
import
find
first
among
newer
agent
develop
treatment
infect
caus
drugresist
gramposit
bacteria
linezolid
daptomycin
tigecyclin
quinupristindalfopristin
exhibit
excel
vitro
activ
mrsa
vre
isol
second
stepwis
increas
mrsa
past
year
emerg
vre
past
year
significantli
associ
increas
hospit
consumpt
sever
class
antimicrobi
agent
particularli
glycopeptid
inhibitor
combin
extendedspectrum
cephalosporin
carbapenem
fluoroquinolon
p
relationship
antimicrobi
use
preval
mrsa
caus
nosocomi
infect
complex
posit
correl
preval
mrsa
antibiot
use
establish
level
hospit
unit
particularli
strong
antibiot
fluoroquinolon
howev
posit
correl
also
found
use
carboxyor
ureidopenicillin
ceftazidim
cefsulodin
amoxicillinclavulan
acid
macrolid
fluoroquinolon
levofloxacin
ciprofloxacin
find
partli
accord
previou
observ
interestingli
despit
vast
increas
mrsa
rate
increas
antibiot
consumpt
organ
continu
fulli
suscept
vancomycin
antibiot
use
also
abl
influenc
nosocomi
vre
epidemiolog
differ
mechan
high
rate
vancomycin
thirdgener
cephalosporin
use
report
associ
increas
preval
vre
hospit
risk
vre
colonis
vari
exposur
differ
antimicrobi
higher
tendenc
promot
colonis
cefotetan
ceftriaxon
ceftazidim
studi
also
confirm
consumpt
fluoroquinolon
inject
ciprofloxacin
alon
posit
correl
increas
rate
vre
research
conduct
clarifi
associ
great
major
linezolidand
vancomycinresist
e
faecium
infect
report
occur
patient
treat
linezolid
patient
without
prior
exposur
linezolid
could
also
acquir
linezolidand
vancomycinresist
e
faecium
infect
via
nosocomi
transmiss
declin
linezolid
suscept
vancomycinresist
e
faecium
report
month
introduct
clinic
use
hospit
linezolid
introduc
clinic
use
although
drug
allow
treatment
vre
infect
patient
mrsa
infect
refractori
intoler
glycopeptid
treatment
fivefold
increas
consumpt
found
compar
routin
test
linezolid
suscept
among
resist
gramposit
bacteria
particularli
among
vancomycinresist
e
faecium
isol
mandatori
perform
hospit
sinc
eightysix
per
cent
mrsa
isol
resist
telithromycin
find
line
previou
global
studi
canton
et
al
demonstr
mrsa
isol
harbour
constitut
macrolidelincosamidestreptogramin
b
mechan
ml
b
resist
phenotyp
also
resist
telithromycin
previou
studi
indic
major
mrsa
isol
taiwan
highli
resist
macrolid
mic
mgl
possess
ml
b
phenotyp
result
daptomycin
suscept
gener
compar
publish
data
clinic
isol
europ
north
american
isol
mrsa
isol
vancomycinresist
e
faecium
suscept
daptomycin
bacteraemia
due
daptomycinresist
mrsa
mic
mgl
emerg
daptomycin
resist
mic
mgl
e
faecium
daptomycin
therapi
previous
report
clinician
microbiologist
awar
exist
potenti
develop
daptomycin
resist
therapi
although
agent
avail
clinic
use
taiwan
find
agreement
observ
mrsa
isol
inhibit
tigecyclin
mgl
vre
isol
inhibit
concentr
mgl
mgl
independ
speci
enterococci
suscept
tetracyclin
phenotyp
resist
result
agreement
previou
find
tigecyclin
prove
activ
drugresist
gramposit
pathogen
includ
mrsa
visa
vre
better
vitro
activ
resist
organ
daptomycin
petersen
et
al
demonstr
activ
daptomycin
mic
mgl
could
improv
equal
tigecyclin
mrsa
strain
test
medium
muellerhinton
broth
supplement
adequ
calcium
mgl
contrast
mic
daptomycin
mrsa
mic
two
visa
isol
determin
presenc
mgl
calcium
test
medium
twofold
higher
tigecyclin
report
two
limit
first
data
could
exclud
possibl
increas
rate
mrsa
may
drive
increas
consumpt
rather
revers
rate
mrsa
alreadi
high
ddd
glycopeptid
consumpt
furthermor
increas
resist
could
gener
trend
happen
worldwid
widespread
use
antimicrobi
might
contribut
partli
trend
second
rate
mrsa
vre
may
overestim
due
possibl
hospitalwid
dissemin
clonallyrel
isol
failur
adher
guidelin
hospit
infect
control
practic
advisori
committe
might
result
increas
hospitalacquir
vre
conclus
implement
programm
improv
antimicrobi
prescript
practic
well
adher
appropri
infect
control
measur
control
spread
mrsa
vre
essenti
compon
effort
allevi
grow
preval
multidrugresist
pathogen
hospit
newer
agent
linezolid
daptomycin
tigecyclin
may
repres
therapeut
option
infect
caus
organ
